Clinical predictors of severe cetuximab-induced rash: Observations from 933 patients enrolled in north central cancer treatment group study N0147

Oncology

Volumn 77, Issue 2, 2008, Pages 120-123

  Jatoi, Aminah ^a   Green, Erin M ^a   Rowland Jr , Kendrith M ^b   Sargent, Daniel J ^a   Alberts, Steven R ^a  

^a MAYO CLINIC   (United States)

^b Carle Cancer Center CCOP   (United States)

Author keywords

Cetuximab; Colon cancer; Epidermal growth factor receptor inhibitors; Rash

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER THERAPY; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PALLIATIVE THERAPY; PERFORMANCE; PHASE 3 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; SKIN TOXICITY; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS;

EID: 67650695000     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229751     Document Type: Article

References (16)

1. Solomon BM, Jatoi A: Rash from EGFR inhibitors: opportunities and challenges for palliation. Curr Oncol Rep 2008; 100: 304-308.
2. Scott J, Dakhil T, Cosgriff T, et al: Cetux-imab + FOLFOX6 as first-line therapy for metastatic colorectal cancer. 2005 ASCO Annu Meet Proc. J Clin Oncol 2005; 23(16S): 3705A.
3. Wagner LL, Lacouture ME: Dermatologic toxicities associated with EGFR inhibitors: the clinical pact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology 2007; 21(suppl 5):34-36.
4. Jatoi A, Nguyen PL: Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008; 13: 1201-1204.
5. Scope A, Agero AL, Dusza SW, et al: Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390-5396.
6. Jatoi A, Rowland K, Sloan JA, et al: Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113: 847-853.
7. Mitchell E, LaCouture M, Shearer H, et al: Updated results of STEPP, a phase 2, open-label study of pre-emptive versus reactive skin toxicity treatment in metastatic colorec-tal cancer (mCRC) patients receiving pani-tumumab + FOLFIRI or irinotecan-only chemotherapy as second-line treatment. 10th World Congr Gastrointestinal Cancer, Barcelona, 2008.
8. Rudin CM, Liu W, Desai A, et al: Pharma-cogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008; 26: 1119-1127.
9. Alberts SR, Sinicrope F, Grothey A: N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer 2005; 5: 211-213.
10. Maindrault-Goebel F, Louvet C, Andŕ T, et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999; 35: 1338-1342.
11. http://ctep.cancer.gov/forms/CTCAEv3.pdf; last accessed November 5, 2008.
12. Wheatley-Price P, Ding K, Seymour L, et al: Erlotinib for advanced non-small cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 2350-2357.
13. Lai SE, Minnelly L, ence of skin color in the development of er-lotinib-induced rash: a report from the SE.RIES clinic. 2007 ASCO Annu Meet Proc,Im-part I. J Clin Oncol 2007; 25(suppl 18S): 9127a.
14. Wacker B, Nagrani T, Weinberg J, et al: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor in two large phase III studies. Clin Cancer Res 2007; 13: 3913-3921.
15. Reenstra WR, Yaar M, Gilchrest BA: Aging effects epidermal growth factor receptor phosphorylation and traffic kinetics. Exp Cell Res 1996; 227: 252-255.
16. Migliaccio A, Castoria G, Di Domenico M, et al: Crosstalk between EGFR and extranucle-ar steroid receptors. Ann NY Acad Sci 2006; 1089: 194-200.